Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RYBELSUS semaglutide 3 mg tablet blister pack - TGA Drug Approval Details

Approvals/TGA/RYBELSUS semaglutide 3 mg tablet blister pack

Approved

STANDARD

RYBELSUS semaglutide 3 mg tablet blister pack

Novo Nordisk Pharmaceuticals Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 30, 2025
Approval ID: 70cace021a40d262
Company: Novo Nordisk Pharmaceuticals Pty Ltd
Type: Standard

Approval Details

Approval Id: 70cace021a40d262
Product Name: RYBELSUS semaglutide 3 mg tablet blister pack
Artg Id: 346198
Artg Name: RYBELSUS semaglutide 3 mg tablet blister pack
Sponsor: Novo Nordisk Pharmaceuticals Pty Ltd
Company Detail Path: /organization/novo-nordisk-pharmaceuticals-pty-limited
Artg Date: 2022-02-07
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

70cace021a40d262

Type

Standard

Back to TGA Approvals